Notice of Extraordinary General Meeting of Hansa Medical AB (publ)
October 20, 2016 02:30 ET
|
Hansa Medical AB
The shareholders of Hansa Medical AB (publ) are summoned to attend the
Extraordinary General Meeting on 21 November 2016, at 10:30 am CET at Hansa
Medical’s offices on Scheelevägen 22, Lund,...
Hansa Medical föreslår riktad nyemission
October 20, 2016 02:30 ET
|
Hansa Medical AB
· Styrelsen för Hansa Medical AB (publ) (”Hansa Medical” eller ”Bolaget”)
föreslår en riktad nyemission av aktier om cirka 185 miljoner kronor.
· Teckningskursen i emissionen föreslås uppgå till 70...
Kallelse till extra bolagsstämma i Hansa Medical AB (publ)
October 20, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) kallar till extra bolagsstämma den 21 november 2016
kl. 10.30 i Hansa Medicals lokaler på Scheelevägen 22 i Lund.
Aktieägarna i Hansa Medical AB (publ) kallas härmed till extra...
Hansa Medical proposes a directed share issue
October 20, 2016 02:30 ET
|
Hansa Medical AB
· The board of directors of Hansa Medical AB (publ) (“Hansa Medical” or the
“Company”) proposes a directed share issue of approximately SEK 185 million.
· The subscription price for the issue is...
Första patienten behandlad med IdeS i fas II-studie i förvärvad Trombotisk Trombocytopen Purpura (TTP)
October 11, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) meddelade idag att den första patienten har behandlats i
en klinisk fas II-studie med IdeS i den akuta autoimmuna sjukdomen förvärvad
Trombotisk Trombocytopen Purpura (TTP) vid...
First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)
October 11, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) today announced that the first patient has been
recruited and treated in a Phase II clinical study with IdeS in the acute
autoimmune disease acquired Thrombotic...
Första patienten behandlad i Hansa Medicals studie Highdes
October 03, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) meddelade idag att den första patienten har behandlats
med läkemedelskandidaten IdeS och därefter njurtransplanteras i
multicenterstudien Highdes för desensitiseing av...
First patient treated in Hansa Medical’s Highdes-study
October 03, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) today announced that the first patient has been treated
and subsequently transplanted in the pivotal multicenter study Highdes using
IdeS to desensitize highly sensitized...
Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented
August 23, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) today announced that preliminary results of the Sweden
based ongoing Phase II study of IdeS were presented today by Professor Gunnar
Tufveson at the 26th International Congress...
Resultat från pågående svenska fas II-studien med IdeS i sensitiserade patienter presenterade
August 23, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) meddelade idag att de preliminära resultaten från den
pågående svenska fas II-studien med IdeS presenterades av professor Gunnar
Tufveson vid 26th International Congress of the...